Benefits of ‘transformational’ cystic fibrosis drug highlighted in new review.
A new systematic review by University of Liverpool researchers highlights the positive impact that triple-combination therapy has on the wellbeing of people with Cystic Fibrosis (CF).
In August 2020, the European Commission formally granted a licence to Kaftrio, the first triple-combination therapy to tackle the underlying cause of CF. The treatment, which combines elexacaftor, tezacaftor and ivacaftor, is now available on the NHS bringing hope to thousands of people living with CF across the UK.
news.liverpool.ac.uk/2021/0...
Cochrane Reviews:
cochranelibrary.com/cdsr/do...
-----------------------------------------------------------------------
Why COVID-19 pneumonia lasts longer, causes more damage than typical pneumonia.
Bacteria or viruses like influenza that cause pneumonia can spread across large regions of the lung within hours. In the modern intensive care unit, these bacteria or viruses are usually controlled either by antibiotics or by the body’s immune system within the first few days of the illness.
But in a study published in Nature on January 11, investigators at Northwestern Medicine show COVID-19 pneumonia is different.
news.northwestern.edu/stori...
Nature. Study Paper:
nature.com/articles/s41586-...
-----------------------------------------------------------------------------
Osteoporosis drug could half number of redo hip replacement operations.
More than half of repeat hip replacement operations could be prevented with a drug already successfully used to treat osteoporosis, new research from the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust has revealed.
An estimated 8,500 hip revision procedures are conducted in England, Wales and Northern Ireland each year at a large cost to the NHS, with repeat procedures also carrying an increased risk of infection and other complications compared to first time surgery.
quadscentral.com/health-new...
---------------------------------------------------------------------------------
UCLA scientists develop method to more efficiently isolate and identify rare T cells.
Scientists from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a technique that will enable researchers to more efficiently isolate and identify rare T cells that are capable of targeting viruses, cancer and other diseases.
The approach could increase scientists' understanding of how these critical immune cells respond to a wide range of illnesses and advance the development of T cell therapies. This includes immunotherapies that aim to boost the function and quantity of cancer or virus-targeting T cells and therapies intended to regulate the activity of T cells that are overactive in autoimmune diseases such as diabetes and multiple sclerosis.
uclahealth.org/ucla-scienti....
Proceedings of the National Academy of Sciences. Research Paper:
pnas.org/content/118/3/e202...
----------------------------------------------------------------------------
Scientists identify “immune cop” that detects SARS-CoV-2.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified the sensor in human lungs that detects SARS-CoV-2 and signals that it’s time to mount an antiviral response. The study, published today in Cell Reports, provides insights into the molecular basis of severe disease and may enable new strategies for the treatment and prevention of COVID-19.
sbpdiscovery.org/news/scien...
Cell Reports. Research Paper:
cell.com/cell-reports/fullt...
----------------------------------------------------------------------------------------------------------
Lipid biomarkers in urine can determine the type of asthma.
n a new study, researchers at Karolinska Institutet in Sweden have used a urine test to identify and verify a patient’s type of asthma. The study, which has been published in the American Journal of Respiratory and Critical Care Medicine, lays the foundation for a more personalized diagnosis and may result in improved treatment of severe asthma in the future.
news.ki.se/lipid-biomarkers...
American Journal of Respiratory and Critical Care Medicine. Research Paper:
Bronchiectasis & Atelectasis update
Update on my nebuliser
Copd emphysema update
